MedPath

Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer

Not Applicable
Terminated
Conditions
Prostate Cancer
Interventions
Dietary Supplement: Beneforte extra broccoli soup
Dietary Supplement: Standard broccoli soup
Registration Number
NCT02404428
Lead Sponsor
Quadram Institute Bioscience
Brief Summary

Prostate cancer is a major public health problem and there is a strong need of new preventive strategies based on drug and lifestyle interventions. It is now well-established that healthy eating patterns and increasing physical activity can prevent or delay prostate cancer progression. Intake of cruciferous vegetables (e.g. broccoli, cabbage, cauliflower, Brussels sprouts, kale) has been associated with decreased risk of prostate cancer progression; however the underlying biological mechanisms remain unknown. The investigators propose to undertake a pilot study on a group of men with early prostate cancer on active surveillance to determine whether a diet rich in broccoli will induce changes in tumor size and blood flow measured by conventional Magnetic Resonance Imaging (MRI) techniques. Men with early prostate cancer on active surveillance who have visible cancer lesions on MRI will be recruited onto this double-blinded randomized intervention and they will be asked to eat one portion of broccoli soup per week for 6 months. The investigators will test two varieties of broccoli (standard and 'Beneforte extra' broccoli) that are able to deliver two different levels of sulforaphane (SF), an active compound extensively studied for its potential anticancer properties. This study will involve MRI scans, blood and urine collection before and after a 6 month intervention period. This study design will not only allow us to observe diet-induced changes within the prostate but also at the systemic level. In addition, participant's lifestyle (habitual diet and physical activity) will be assessed by food diaries and exercise questionnaires.

This study has been funded by Biotechnology and Biological Sciences Research Council (BBSRC) and Prostate Cancer foundation (PCF).

Detailed Description

The study is a randomised double-blinded dietary intervention study. The study population will consist of men (n=20) aged 18-80 years with a BMI between 19.5 and 35 kg/m2 with low risk prostate cancer (prostate specific antigen \[PSA\] \< 10ng/ml; Gleason grade 6; T category T1 or T2) or intermediate risk prostate cancer patients (PSA 10-20ng/ml; Gleason 7 (including selected 4+3 cases that will not be advised for radical prostatectomy; T category T1 or T2) who have visible lesions on MRI and have already decided to take up active surveillance/monitoring. The investigators chose these inclusion criteria because they reflect the population of men on active surveillance that the investigators are currently recruiting in the ESCAPE study (Effect of Sulforaphane on Prostate CAncer PrEvention; ClinicalTrials.gov Identifier: NCT01950143) via the Norfolk and Norwich University Hospital. Volunteers recruited onto this study will be randomly allocated to one of two arms in which they will be required to consume one portion of broccoli soup per week, delivering different levels of glucoraphanin (SF precursor) in each study arm. This will be part of their normal diet for 6 months. The two soups will contain standard broccoli (i), or glucoraphanin-enriched broccoli named for the study 'Beneforte extra' (ii). The study will involve MRI monitoring at baseline and after 6 months. In addition the investigators will collect blood and urine samples at baseline and after 6 months. The volunteers' habitual diet and physical activity will also be assessed during the intervention period.

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
5
Inclusion Criteria
  • Suitable for and have chosen AS as management for localised prostate cancer
  • MRI visible detected lesion ≥0.5 cm in the axial plane, corresponding to the biopsy confirmed region of prostate cancer
  • No contraindication to MR scanning
  • Aged 18-80 years
  • BMI between 19.5 and 35 kg/m2
  • Smokers and non-smokers
Exclusion Criteria
  • 5α-reductase inhibitors or testosterone replacement medicines
  • warfarin
  • surgically implanted pelvic metalwork
  • pacemakers or other implanted electronic devices not compatible with MRI
  • contra-indications to gadolinium-based contrast agents (including patients with abnormal renal function)
  • Glomerular Filtration Rate (GFR) <60 ml/min
  • claustrophobia
  • allergies to any of the ingredients of the broccoli soups
  • dietary supplements or herbal remedies which may affect the study outcome - unless the volunteer is willing to discontinue taking them for 1 month prior to starting study
  • parallel participation in another research project that involves dietary intervention

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
beneforte extra broccoli soupBeneforte extra broccoli soupone portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
standard broccoli soupStandard broccoli soupone portion (300 g each) per week of a soup containing standard broccoli
Primary Outcome Measures
NameTimeMethod
tumor size/blood flow6 months

change in prostate tumor/blood flow size determined by MRI methods within the prostate gland

Secondary Outcome Measures
NameTimeMethod
GSTM1 genotype6 months

Glutathione S-transferase Mu 1 (GSTM1) genotype or other relevant genotypes on mediating metabolite changes by diet

choline + creatine/citrate ratio6 months

concentration of metabolites (choline + creatine/citrate ratio) in the prostate tissue determined by using MR spectroscopy

citrate levels6 months

concentration of citrate and associated metabolites in body fluids (blood, urine)

PSA levels6 months

plasma levels of prostate-specific antigen (PSA) and other blood markers

Trial Locations

Locations (1)

Cambridge University Hospitals NHS Foundation Trust_Addenbrooke's Hospital

🇬🇧

Cambridge, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath